As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. Our product candidates and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe.
|Bank Name||MacroGenics, Inc.|
|CEO||Dr. Scott Koenig|